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Abstract
Background: Given the important contribution of the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase system to the generation of reactive oxygen species induced by hepatitis C virus (HCV), we investigated
two single nucleotide polymorphisms (SNPs) in the putative regulatory region of the genes encoding NADPH
oxidase 4 catalytic subunit (NOX4) and its regulatory subunit p22phox (CYBA) and their relation with metabolic and
histological variables in patients with HCV.
Methods: One hundred seventy eight naïve HCV patients (49.3% male; 65% HCV genotype 1) with positive
HCV RNA were genotyped using specific primers and fluorescent-labeled probes for SNPs rs3017887 in NOX4
and −675 T→ A in CYBA.
Results: No association was found between the genotype frequencies of NOX4 and CYBA SNPs and inflammation scores
or fibrosis stages in the overall population. The presence of the CA + AA genotypes of the NOX4 SNP was nominally
associated with a lower alanine aminotransferase (ALT) concentration in the male population (CA + AA = 72.23 ± 6.34 U/L
versus CC = 100.22 ± 9.85; mean ± SEM; P = 0.05). The TT genotype of the CYBA SNP was also nominally associated with a
lower ALT concentration in the male population (TT = 84.01 ± 6.77 U/L versus TA + AA = 109.67 ± 18.37 U/L; mean ± SEM;
P = 0.047). The minor A-allele of the NOX4 SNP was inversely associated with the frequency of metabolic syndrome (MS)
in the male population (odds ratio (OR): 0.15; 95% confidence interval (CI): 0.03 to 0.79; P = 0.025).
Conclusions: The results suggest that the evaluated NOX4 and CYBA SNPs are not direct genetic determinants of fibrosis
in HCV patients, but nevertheless NOX4 rs3017887 SNP could indirectly influence fibrosis susceptibility due to its inverse
association with MS in male patients.
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Background
Chronic infection with hepatitis C virus (HCV) affects
approximately 170 million people worldwide, and it is
associated with increased morbidity and mortality sec-
ondary to cirrhosis and hepatocarcinoma (HCC) [1]. In
Brazil, the national survey of viral hepatitis has shown
an overall prevalence of positive HCV antibody of 1.38%
[2]. The viral chronic infection stimulates a general
tissue response, which includes oxidative stress as one of
the pathogenic feature. HCV proteins stimulate the
generation of reactive oxygen species (ROS) in infected
tissue [3-6], and different cell types (hepatocyte and
nonhepatocyte) contribute to hepatic oxidative stress
in this condition [7].
It has been already demonstrated that HCV increases
mitochondrial ROS production following mobilization of
intracellular calcium. Another ROS source in HCV infection
are nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX) proteins [7], membrane-associate proteins
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that transfer electrons across membranes and catalyze
the NADPH-dependent reduction of O2 to O2
−. Not
only NOX2, the prototype of NADPH oxidase family,
is expressed in the liver (hepatocytes, Kupffer cells,
quiescent and activated hepatic stellate cells (HSC),
and endothelial cells), but also the isoforms NOX1 and
NOX4 [8], like NOX2, require association with another
membrane-associate protein, subunit p22phox, encoded
by the CYBA gene [9]. HCV was shown to elicit a persist-
ent augment not only of NOX1 and NOX4 in hepatocytes
in vitro and in the human liver but also of p22phox and
other components of the NADPH oxidase system [10].
Thus, given the important contribution of the NADPH
oxidase system to the oxidative stress induced by HCV
infection, the aim of the present study was to evaluate
association of two single nucleotide polymorphisms
(SNPs) in the genes encoding NOX4 and p22phox (CYBA)
with metabolic and histological variables in patients with
chronic hepatitis C. NOX4 rs3017887 was chosen because
it was the most informative SNP (able to capture 12 out of
124 SNPs with minor allele frequency of at least 0.05)
from a haplotype block comprised of four SNPs possibly
associated with oxidative burden [11]. CYBA −675 T→A
(unregistered) was chosen because it was previously
shown to be functional, with the T allele associated
with a higher phagocytic NADPH-dependent super-
oxide production [12].
Methods
Patients
We studied 178 patients with chronic hepatitis C infection
(CHC) from the Northeast of Brazil. All patients enrolled
had tested positive for anti-HCV antibodies (third-generation
enzyme immunoassay, Abbott Laboratories, Chicago, USA)
and HCV-RNA (RT-PCR, Roche Cobas Amplicor 2.0, Roche
Diagnostics, Basel, Switzerland). All studied patients were
naïve to anti-HCV therapy and did not present severe
leucopenia, anemia, or plaquetopenia. The HCV geno-
type was determined by LiPA assay (Innolipa HCV II;
Immunogenetics, Ghent, Belgium). All patients were
enrolled at the Liver Institute of Pernambuco from
February 2012 to October 2013.
This cross-sectional study was conducted according to
the Helsinki declaration of 1975. Specific informed con-
sent was obtained from all included patients, and the
protocol was approved by the Internal Review Board of
the University of Pernambuco - Brazil.
Other causes of liver disease were excluded after clinical,
laboratory (viral serology, autoantibody titers, serum iron,
ferritin and transferrin saturation, ceruloplasmin, cop-
per and alpha1-antitrypsin concentrations), and image
(hepatobiliary system ultrasound) examination. Patients
who had a >100 g/week alcohol intake determined by a
detailed personal history, questioning of family members,
and an investigation of previous medical records were
excluded.
Study design and laboratory assays
Serum samples were collected at the time of liver biopsy
and used to determine total cholesterol, low-density lipo-
protein (LDL), high-density lipoprotein (HDL), triglycerides
(Tg), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), gamma-glutamyl transferase (GGT),
alkaline phosphatase (ALP), and fasting plasma glucose.
Biochemical analyses were performed by standard methods
using automated techniques (Cobas, Roche), and LDL con-
centrations were determined by the Friedwald equation
[13]. HCV genotypes were determined by the INNO-LiPA
HCV II kit (Versant, Bayer Diagnostics, Tarrytown, NY,
USA) according to manufacturer’s instructions [14].
Diagnosis of type 2 diabetes mellitus (T2D), hyperten-
sion, and dyslipidemia was based on the criteria of the
American Diabetes Association (Alexandria, VA, USA).
The diagnosis of metabolic syndrome (MS) was conducted
in accordance with the recommendations of the modified
Adult Treatment Panel III (ATP III) criteria and required
the presence of at least three of the following: a fasting
plasma glucose ≥110 mg/dL, blood pressure ≥135/85mmHg,
Tg ≥150 mg/dL, HDL <40 mg/dL in men or <50 mg/dL
in women, and waist circumference ≥ 102 cm in men
or ≥88 cm in women [15].
Genotype analysis
Two SNPs in the putative regulatory region of the
genes encoding NADPH oxidase 4 catalytic subunit
(NOX4) (rs3017887) and its regulatory subunit p22phox
(CYBA) were selected based on previous studies [11,12].
The samples were genotyped by real-time PCR using
fluorescent-labeled probes according to the procedures rec-
ommended by the manufacturer. NOX4 rs3017887 was ge-
notyped by assay type validation (C_15762095; Applied
Biosystems, Foster City, USA), and CYBA −675 T→A (un-
registered) was genotyped by PCR using specific primers
(sense: 5′-GCGCTGGCTCACCAC-3′ and antisense: 5′-A
CTGGGAAAGCACAGAATGCA-3′) and fluorescent-
labeled probes (VIC: 5′-CCTCCCGAACCCAGG-3′ and
FAM: 5′-CCTCCCGTACCCAGG-3′) (TaqMan, Applied
Biosystems). Amplifications were performed on an Applied
Biosystems Step One Plus Real-Time PCR System (30 s
at 60°C, 10 min at 95°C, followed by 40 cycles of PCR
(15 s at 95°C followed by 60 s at 60°C) and 30 s at 60°C).
Genotyping success rates were 98% for both SNPs,
and the distribution of genotypes was consistent with
Hardy-Weinberg equilibrium for the two evaluated SNPs.
Histological analysis
The liver tissue was fixed in 4% formaldehyde and proc-
essed for hematoxylin-eosin and Masson trichrome stains
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for histological analysis. Histological analyses were evalu-
ated by only one pathologist who was unaware of the
HCV genotype and of the patient’s clinical characteristics.
Stages of fibrosis and grades of inflammation were
scored according to METAVIR (F0: no fibrosis, F1:
portal fibrosis without septa, F2: portal fibrosis with
few septa, F3: numerous septa without cirrhosis, and
F4: cirrhosis) [16]. Patients with histological evidence
of non-alcoholic steatohepatitis (NASH) were excluded
from the study.
Statistical analysis
Results are expressed as mean ± SD except where stated
otherwise. Continuous variables were log-transformed for
the analysis when normal distribution was rejected by
Shapiro-Wilk W test. Fisher’s chi square test, ANOVA,
and ANCOVA were used for comparisons between
groups. Odds ratios (OR) and 95% confidence intervals
(CIs) were computed in the analysis for the minor al-
leles. Adjustments for clinical and biological variables
were carried out by including them as covariates in the re-
gressive model. Interaction between sex and genotype was
assessed by including in the regression models (ANCOVA
or logistic regression) a ‘crossed’ compound covariate (sex/
genotype). The stratification by sex was then performed
by nesting the genotype variable within the sex variable in
the analysis model, resulting in the computation of statis-
tical effects for men and women separately, and adjusted
for multiple comparisons due to the stratification by sex.
Moreover, as two independent SNPs were tested, a Bon-
ferroni correction was applied: P ≤ 0.025 was considered
significant, unless stated otherwise. The power to de-
tect sex-specific associations of the SNPs with MS was
approximately 40%, for an OR ≥1.5 and alpha = 0.05.
Statistics were performed with the JMP software (SAS
Institute Inc., Cary, NC, USA).
Table 1 Clinical and biochemical variables according to the grade of fibrosis in patients with chronic hepatitis C
F1 F2 F3 F4 P value
N 52 53 37 36
Age* 53 ± 13 56 ± 9 60 ± 8 59 ± 11 0.05
Gender: M/F (%) 44/56 57/43 38/62 53/47 0.29
HCV genotype 1 (%) 57.7 56.6 78.4 75 0.18
HCV genotype 2 (%) 7.7 3.8 2.7 5.6
HCV genotype 3 (%) 34.6 39.6 18.9 18.4
Alcohol consumption (%) 58/27/15 49/32/19 67/19/14 61/11/28 0.38
Tabagism (%) 33/8/59 47/11/41 38/8/54 31/8/61 0.58
Type 2 diabetes (%) 15 26 16 19 0.49
Hypertension (%) 31 41 56 42 0.14
Metabolic syndrome (%) 12 26 39 28 0.03
Hepatocarcinoma (%) 0 0 0 31 <0.001
*BMI (kg/m2) 26.49 ± 3.93 26.17 ± 3.68 26.76 ± 5.43 26.67 ± 4.40 0.94
Waist circumference (cm) 91.29 ± 11.53 92.07 ± 9.14 94.32 ± 13.18 95.78 ± 11.45 0.28
TC (mg/dL)* 169 ± 34 169 ± 36 174 ± 55 151 ± 33 0.12
LDL (mg/dL)* 101 ± 33 100 ± 37 107 ± 50 82 ± 23 0.08
HDL (mg/dL) 52 ± 15 47 ± 16 47 ± 19 49 ± 20 0.23
Triglycerides (mg/dL)* 91 ± 31 139 ± 145 115 ± 50 90 ± 30 0.34
Fasting glucose (mg/dL)* 96 ± 36 101 ± 32 101 ± 33 102 ± 25 0.36
ALT (U/L) 70 ± 36 96 ± 59 86 ± 57 84 ± 54 0.22
AST (U/L) 49 ± 25 71 ± 52a 84 ± 49a 101 ± 74a,b <0.0001
GGT (U/L) 67 ± 50 98 ± 108 122 ± 86a 150 ± 123a,b <0.0001
ALP (U/L)* 78 ± 60 95 ± 65 92 ± 48 139 ± 80a,b,c <0.0001
Results are expressed as mean ± SD. For the continuous variables analysis, Shapiro-Wilk W test was tested, and variable failing in this test was log transformed. If
even so the normality was not verified, nonparametric tests were applied for these variables (indicated by *). ANOVA analysis or Kruskal-Wallis tests were performed,
and the Tukey-Kramer HSD or Dunn test was used when significant differences were observed between the groups, being F1 (a), F2 (b), and F3 (c). Classes for ethnicity:
Caucasoid, Negroid, and African descendant. Classes for alcohol: no drinking, <40 g/d, >40 g/d. Classes for smoke: ex-smoker, smoker, never-smoker. Abbreviations:
GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; TC, total cholesterol; BMI, body mass index. Reference range: Glycemia ≤100 mg/dL; Triglycerides ≤150 mg/dL; HDL ≥40 mg/dL;
LDL-C ≤130 mg/dL; TC ≤200 mg/dL; AST: Male 10 to 34 U/L, Female 10 to 36 U/L; ALT: Male 10 to 44 U/L, Female 10 to 36 U/L; GGT: Male 11 to 50 U/L, Female 7
to 32 U/L; ALP: Male 40 to 129 U/L, Female 35 to 104 U/L. P< 0.05 was considered significant (italicized data).
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Results
The clinical and biochemical variables according to the
grade of fibrosis are demonstrated in Table 1. Patients
with fibrosis grade F3/F4 were older than patients with
fibrosis grade F1/F2; AST, GGT, and ALP concentrations
increased with the severity of fibrosis. The frequency
of MS was significantly higher in patients with fibrosis
grade F3/F4, and the frequency of HCC was significantly
higher in patients with fibrosis grade F4.
No associations were found between the genotype
frequencies of NOX4 rs3017887 (CC versus CA + AA)
and CYBA −675 T→ A (TT versus TA + AA) SNPs and
inflammation scores (OR: 0.99; 95% CI: 0.45 to 2.14; P= 0.97
and OR: 0.99; 95% CI: 0.33 to 2.75; P= 0.99, for NOX4 and
CYBA, respectively) or fibrosis stages (Table 2) in the overall
population and in the population stratified by sex or by
HCV genotypes. In the male population, the CA + AA
genotypes of the NOX4 SNP presented a nominal (P > 0.025
to P ≤ 0.05) association with a lower ALT concentration
(CA+AA: 72.23 ± 6.34 U/L versus CC: 100.22 ± 9.85 U/L;
mean ± SEM; P = 0.05). The TT genotype of the CYBA
SNP was also associated with a lower ALT concentra-
tion (TT = 84.01 ± 6.77 U/L versus TA + AA = 109.67 ±
18.37 U/L; mean ± SEM; P = 0.05) (Table 3).
Table 4 shows the genotype frequencies of NOX4
rs3017887 SNP according to the MS status in the popu-
lation stratified by sex; we observed a lower frequency of
MS in male patients carrying the genotypes CA + AA
(CA +AA: 13.8% versus CC: 25.0%). This lower prevalence
was confirmed in a dominant model of logistic regression
analysis demonstrating a protective effect for the minor
A-allele (OR: 0.15; 95% CI: 0.03 to 0.79; P = 0.025). No
associations were found between the SNPs and the MS
status when the population was stratified by HCV
genotype.
Discussion
The association between HCV and metabolic factors has
been recognized as a two-way road. On the one hand,
HCV infection is able to induce insulin resistance, stea-
tosis, and diabetes; on the other hand, metabolic factors
such as insulin resistance may modulate the clinical
course of HCV infection, increasing the predisposition
to hepatic fibrosis and to HCC [17]. Accordingly to
these observations, MS was significantly more frequent
in patients with F3/F4 in the present series. Interestingly,
we found an association of the minor A-allele of NOX4
rs3017887 with a lower prevalence of MS in this cohort
of CHC patients, while no associations were observed
Table 2 Genotype frequencies by fibrosis grade in
patients with chronic hepatitis C
F1 and F2 F3 and F4 OR (95% CI) P value
NOX4 (rs3017887) N = 105 N = 73 0.60 (0.22 to 1.59) 0.31
CC 0.532 0.588
CA 0.457 0.372
AA 0.011 0.040
MAF 0.239 0.226
CYBA (675 T→ A) 0.29 (0.06 to 1.11) 0.09
TT 0.800 0.882
TA 0.190 0.118
AA 0.010 0.000
MAF 0.105 0.059
Genotype frequencies of NOX4 rs3017887 and of CYBA −675 T→ A
(unregistered) single nucleotide polymorphisms by fibrosis grade in patients
with chronic hepatitis C. Odds ratio (OR) and 95% confidence interval (95% CI)
for the minor allele of the genotyped SNPs in a dominant model of logistic
regression analysis adjusted for age, gender, metabolic syndrome status,
triglycerides, plasmatic albumin concentrations, and HCV genotype. MAF,
minor allele frequency (frequency of the rarer allele, A for both SNPs).
Table 3 Alanine aminotransferase (ALT) concentrations in
male patients with chronic hepatitis C
ALT (U/L) P value
NOX4 (rs3017887)a
CC 100.22 ± 9.85 0.05
CA/AA 72.23 ± 6.34
CYBA (−675 T→ A)b
TT 84.01 ± 6.77 0.05
TA/AA 109.67 ± 18.37
Alanine aminotransferase (ALT) concentrations in male patients with
chronic hepatitis C according to the genotype of NOX4 rs3017887 and
CYBA −675 T→ A single nucleotide polymorphisms. Results are mean ± SEM.
aANCOVA adjusted for age, gender, metabolic syndrome status, gamma glutamyl
transferase, and HCV genotype. bANCOVA adjusted for age, gender, metabolic
syndrome status, systolic blood pressure, plasmatic albumin concentration, body
mass index, and HCV genotype.
Table 4 Genotype frequencies of NOX4 rs3017887 single
nucleotide polymorphism by metabolic syndrome (MS)
status
NOX4 (rs3017887) Absence
of MS
Presence
of MS
OR (95% CI) P value
Female (N = 63) (N = 25) 1.71 (0.48 to 6.00) 0.40
CC 0.540 0.476
CA 0.440 0.524
AA 0.020 0.000
MAF 0.240 0.321
Male (N = 66) (N = 17) 0.15 (0.03 to 0.79) 0.025
CC 0.545 0.714
CA 0.436 0.286
AA 0.018 0.000
MAF 0.236 0.143
Genotype frequencies of NOX4 rs3017887 single nucleotide polymorphism by
metabolic syndrome (MS) status in patients with chronic hepatitis C. Odds
ratio (OR) and 95% confidence interval (95% CI) for the minor allele of
rs3017887 SNP in a dominant model of logistic regression analysis adjusted for
age, gender, type 2 diabetes status, body mass index and HCV genotype. MAF,
minor allele frequency (frequency of the rarer allele, A for both SNPs).
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between rs3017887 and inflammation scores or fibrosis
stages.
We have no definitive explanation for the protective
effect exerted by the A-allele of NOX4 rs3017887 regard-
ing MS, especially because this same SNP did not influ-
ence the frequency of MS in patients with non-alcoholic
fatty liver disease (data not shown). One possibility is
that this SNP manifests its effects only in presence of a
stronger insult such as the viral infection; in other
words, this may be a case of a gene (NOX4 rs3017887)-
environment (HCV) interaction: the SNP and HCV
jointly influence the risk of developing MS, as already
described for other conditions, for example, two SNPs
in the CYP1A1 gene that are associated with increased
risk of HCC only in cigarette smoking subjects [18].
The modulation of the risk for MS by a variant in a
gene encoding a protein from NADPH oxidase family is
plausible because this pro-oxidant system is a major
source of ROS in this metabolic condition [19]. It is
noteworthy that no associations were found between
NOX4 rs3017887 and any of the components of MS
alone, maybe because the SNP exerts a weak pleiotropic
effect on each one of the MS traits that becomes notice-
able only when the traits are considered together. The
C-allele of rs3017887 was described in a haplotype block
of four SNPs possibly associated with oxidative burden
[11]; thus, it is feasible that the A-allele is associated with
a lower oxidative stress. However, as far as we know, a dir-
ect functional repercussion of NOX4 rs3017887 has never
been demonstrated; and it is also possible that this SNP is
not causative but a marker of another functional variant
in linkage disequilibrium with it. Why the association was
observed in a sex-specific manner remains to be further
elucidated, but two of us (TP and MLCG) already observed
a sex-specific association of other pathological condition
with genes associated with the redox state [20].
Other positive findings of the present study were the
nominal associations of the genotypes CA +AA of NOX4
rs3017887 and of the genotype TT of CYBA −675 T→A
with lower ALT concentrations. The association of the A-
allele of rs3017887 is easier to understand since a lower
necrosis activity could take place in the context of a
lower oxidative burden [21]. However, the T-allele of
CYBA −675 T→ A has been previously associated with
a higher NADPH-dependent superoxide production in
peripheral monocytes and lymphocytes [12], which
makes its association with lower ALT concentrations
unexpected. Nevertheless, the functional effect of a
genomic variant in one cell type does not necessarily
mean the same functional effect in another cell type
[22], and the functional repercussions of CYBA −675 T→
A in hepatocytes has never been explored. Interestingly,
CYBA was recently identified as a host factor implicated in
HCV entry in hepatocytes, but the mechanisms underlying
its participation in viral infection are currently unknown
[23]. We speculate that CYBA not only takes part in HCV
entry, but variations in its expression level could also
modulate hepatocyte responses to HCV infection, which
could explain, for instance, a greater or lesser necrosis ac-
tivity in different individuals with distinct genetic variants.
Conclusions
The results of the present study should be interpreted in
the context of limitations imposed by the small number
of patients, such as the low statistical power. Our find-
ings suggest that the evaluated NOX4 and CYBA SNPs
are not direct genetic determinants of inflammation or
fibrosis in HCV patients. However, in male patients with
CHC, NOX4 rs3017887 SNP could indirectly influence
fibrosis susceptibility due to its inverse association with
MS in male patients.
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